StocksMedium•14 November 2026•
1 min read
COSCIENS Biopharma Reports $3.45 GAAP EPS Loss in Third Quarter
Key Facts
1COSCIENS Biopharma reported a GAAP EPS loss of $3.45 for the quarter.
2The company's revenue reached $2.5 million for the period.
COSCIENS Biopharma reported a GAAP EPS loss of $3.45 for the third quarter. Seeking Alpha reported that the company's revenue reached $2.5 million during the specified period.
CSCIF closed at $5.79 on November 12, 2026, prior to the release of these results. The financial figures are part of the standard quarterly earnings cycle for publicly traded biotechnology firms.